• Repression of Transcription at DNA Breaks Requires Cohesin throughout Interphase and Prevents Genome Instability. 

  Meisenberg, C; Pinder, SI; Hopkins, SR; Wooller, SK; Benstead-Hume, G; Pearl, FMG; Jeggo, PA; Downs, JA (2019-01-17)

  Cohesin subunits are frequently mutated in cancer, but how they function as tumor suppressors is unknown. Cohesin mediates sister chromatid cohesion, but this is not always perturbed in cancer cells. Here, we identify a ...
• Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. 

  Bahig, H; Yuan, Y; Mohamed, ASR; Brock, KK; Ng, SP; Wang, J; Ding, Y; Hutcheson, K; McCulloch, M; Balter, PA; Lai, SY; Al-Mamgani, A; Sonke, J-J; van der Heide, UA; Nutting, C; Li, XA; Robbins, J; Awan, M; Karam, I; Newbold, K; Harrington, K; Oelfke, U; Bhide, S; Philippens, MEP; Terhaard, CHJ; McPartlin, AJ; Blanchard, P; Garden, AS; Rosenthal, DI; Gunn, GB; Phan, J; Cazoulat, G; Aristophanous, M; McSpadden, KK; Garcia, JA; van den Berg, CAT; Raaijmakers, CPJ; Kerkmeijer, L; Doornaert, P; Blinde, S; Frank, SJ; Fuller, CD (2018-11)

  Background: Current standard radiotherapy for oropharynx cancer (OPC) is associated with high rates of severe toxicities, shown to adversely impact patients' quality of life. Given excellent outcomes of human papilloma ...
• Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). 

  Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; de Baere, T; Robert, C; Ascierto, PA; Baurain, J-F; Imperiale, M; Rahimian, S; Tersago, D; Klumper, E; Hendriks, M; Kumar, R; Stern, M; Öhrling, K; Massacesi, C; Tchakov, I; Tse, A; Douillard, J-Y; Tabernero, J; Haanen, J; Brody, J (2018-11-01)

  A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were ...
• Ultrahigh Dose-rate Radiotherapy: Next Steps for FLASH-RT. 

  Harrington, KJ (2019-01-01)

  A new way of delivering radiotherapy at very high dose rates is described and compared with conventional radiotherapy. The ultrahigh dose-rate therapy reduces damage to normal pig skin and exerts potent activity against ...
• CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. 

  Gillison, ML; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Iglesias Docampo, LC; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Li, L; Ferris, RL (2018-09)

  Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) ...
• The immunological consequences of radiation-induced DNA damage. 

  Wilkins, AC; Patin, EC; Harrington, KJ; Melcher, AA (2019-01-10)

  Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell-autonomous mechanisms of cell death. Here, tumour cell death occurs when a threshold number of radiation-induced non-reparable ...
• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 

  Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Lynch, M; Jayaprakash, V; Li, L; Gillison, ML (2018-06)

  OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ...
• Patient-reported outcomes with nivolumab in advanced solid cancers. 

  Tykodi, SS; Schadendorf, D; Cella, D; Reck, M; Harrington, K; Wagner, S; Shaw, JW (2018-11)

  Patients with recurrent or metastatic cancer commonly suffer from debilitating toxicity associated with conventional treatment modalities, as well as disease-related symptoms, often with a concomitant negative impact on ...
• Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams). 

  Grønhøj, C; Jensen, DH; Dehlendorff, C; Marklund, L; Wagner, S; Mehanna, H; Munck-Wikland, E; Ramqvist, T; Näsman, A; Wittekindt, C; Würdemann, N; Sharma, SJ; Gattenlöhner, S; Kiss, K; Andersen, E; Spruce, R; Batis, N; Robinson, M; Harrington, K; Winter, S; Jones, TM; Klussmann, JP; Dalianis, T; Friborg, J; von Buchwald, C (2018-06)

  BACKGROUND: The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could ...
• Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 

  Cohen, EEW; Soulières, D; Le Tourneau, C; Dinis, J; Licitra, L; Ahn, M-J; Soria, A; Machiels, J-P; Mach, N; Mehra, R; Burtness, B; Zhang, P; Cheng, J; Swaby, RF; Harrington, KJ; KEYNOTE-040 investigators (2019-01-12)

  BACKGROUND: There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. ...
• Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. 

  Mehanna, H; Robinson, M; Hartley, A; Kong, A; Foran, B; Fulton-Lieuw, T; Dalby, M; Mistry, P; Sen, M; O'Toole, L; Al Booz, H; Dyker, K; Moleron, R; Whitaker, S; Brennan, S; Cook, A; Griffin, M; Aynsley, E; Rolles, M; De Winton, E; Chan, A; Srinivasan, D; Nixon, I; Grumett, J; Leemans, CR; Buter, J; Henderson, J; Harrington, K; McConkey, C; Gray, A; Dunn, J; De-ESCALaTE HPV Trial Group (2019-01-05)

  BACKGROUND: The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed ...
• Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. 

  Dillon, MT; Grove, L; Newbold, KL; Shaw, H; Brown, NF; Mendell, J; Chen, S; Beckman, RA; Jennings, A; Ricamara, M; Greenberg, J; Forster, M; Harrington, KJ (2019-01-15)

  PURPOSE: Patritumab plus cetuximab with platinum as first-line therapy for patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) was evaluated for safety and to determine the ...
• Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts 

  Calvo, F; Ferrari, N; Ranftl, R; Chicherova, I; Slaven, ND; Moeendarbary, E; Farrugia, AJ; Lam, M; Semiannikova, M; Westergaard, MCW; Tchou, J; Magnani, L

  Aggressive behaviours of solid tumours are influenced by the tumour microenvironment. Multiple signalling pathways can influence the behaviour of stromal fibroblasts in tumours, but how these events are coordinated to ...
• Regulation of mechanotransduction: Emerging roles for septins 

  Lam, M; Calvo, F
• Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

  Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)

  Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
• Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. 

  Owen, C; Constantinidou, A; Miah, AB; Thway, K; Fisher, C; Benson, C; Zaidi, S; Messiou, C; VAN DER Graaf, WTA; Jones, RL (2018-09)

  BACKGROUND/AIM: Synovial sarcoma is a soft tissue sarcoma that tends to affect young adults. There are few reports on primary synovial sarcoma of the thyroid and the aim of this study was to document the clinical and ...
• Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). 

  Nutting, CM; Morden, JP; Beasley, M; Bhide, S; Cook, A; De Winton, E; Emson, M; Evans, M; Fresco, L; Gollins, S; Gujral, D; Harrington, K; Joseph, M; Lemon, C; Luxon, L; van den Blink, Q; Mendes, R; Miah, A; Newbold, K; Prestwich, R; Robinson, M; Sanghera, P; Simpson, J; Sivaramalingam, M; Srihari, NN; Sydenham, M; Wells, E; Witts, S; Hall, E; COSTAR Investigators (2018-11)

  PURPOSE: About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the ...
• Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. 

  Chew, W; Benson, C; Thway, K; Hayes, A; Miah, A; Zaidi, S; Lee, ATJ; Messiou, C; Fisher, C; van der Graaf, WT; Jones, RL (2018-09-05)

  BACKGROUND: Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy of ...
• Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. 

  Pender, A; Davis, EJ; Chauhan, D; Messiou, C; Al-Muderis, O; Thway, K; Fisher, C; Zaidi, S; Miah, A; Judson, I; van der Graaf, W; Keedy, VL; Benson, C; Jones, RL (2018-08-20)

  The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following ...
• Dicentric Dose Estimates for Patients Undergoing Radiotherapy in the RTGene Study to Assess Blood Dosimetric Models and the New Bayesian Method for Gradient Exposure. 

  Moquet, J; Higueras, M; Donovan, E; Boyle, S; Barnard, S; Bricknell, C; Sun, M; Gothard, L; O'Brien, G; Cruz-Garcia, L; Badie, C; Ainsbury, E; Somaiah, N (2018-09-20)

  The RTGene study was focused on the development and validation of new transcriptional biomarkers for prediction of individual radiotherapy patient responses to ionizing radiation. In parallel, for validation purposes, this ...

View more